

Short-Acting Beta2 Agonists (SABA)

SALBUTAMOL		TERBUTALINE	
Respigen®	SalAir®	Ventolin®	Bricanyl®
			
100 mcg	100 mcg	250 mcg	250 mcg
Aerosol inhaler		Turbuhaler®	

Short-Acting Muscarinic Antagonists (SAMA)

IPRATROPIUM

Atrovent®




20 mcg

Aerosol inhaler

Combination SABA + SAMA

SALBUTAMOL + IPRATROPIUM

Duolin HFA®




100 mcg/20 mcg

Aerosol inhaler

Inhaled Corticosteroids (ICS)


FLUTICASONE propionate

Flixotide®



50 mcg 125 mcg 250 mcg

Aerosol inhaler



50 mcg 100 mcg 250 mcg

Accuhaler®

BUDESONIDE

Pulmicort®




100 mcg 200 mcg 400 mcg

Turbuhaler®


BECLOMETHASONE dipropionate

Beclazone®



50 mcg 100 mcg 250 mcg

Qvar® (ultrafine particle)




50 mcg 100 mcg

Note: Beclazone® and Qvar® are not dose equivalent and are not interchangeable

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)


FLUTICASONE propionate + SALMETEROL

Seretide®



50/25 125/25 250/25

Aerosol inhaler



100/50* 250/50*

Accuhaler®

*100/50 and 250/50 accuhaler only funded if no more than 2 doses per day

FLUTICASONE furoate + VILANTEROL

Breo Ellipta®



100 mcg/25 mcg

Dry powder inhaler

Note: 200 mcg/25 mcg strength available but not funded

Vannair®




100/6 200/6

Aerosol inhaler

BUDESONIDE + FORMOTEROL

Symbicort®



100/6 200/6 400/12*

Turbuhaler®

DuoResp Spiromax®



200/6 400/12*

Dry powder inhaler

*Symbicort 400/12 and DuoResp Spiromax 400/12 only funded if no more than 2 doses per day
Note: Symbicort 100/6, 200/6 and DuoResp Spiromax 200/6 are currently approved for Anti-Inflammatory Reliever (AIR) therapy. Vannair 100/6 and 200/6 is approved for maintenance use, but its use in AIR therapy is an unapproved indication.

Long-Acting Beta2 Agonists (LABA)

SALMETEROL

Serevent®



25 mcg 50 mcg

Aerosol inhaler Accuhaler®

FORMOTEROL (eformoterol)

Oxis®



6 mcg

Turbuhaler®



12 mcg

Aerolizer device®

INDACATEROL





Onbrez Breezhaler®



150 mcg 300 mcg

Breezhaler®

Long-Acting Muscarinic Antagonists (LAMA)

TIOTROPIUM	UMECLIDINIUM	GLYCOPYRRONIUM
Spiriva®	Spiriva Respimat®	Incruse Ellipta®
		
18 mcg	2.5 mcg	62.5 mcg
Handihaler®	Fine mist inhaler	Dry powder inhaler
		Seebri Breezhaler®
		
		50 mcg
		Breezhaler®

Funded by Endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription). Not subsidised if patient is also receiving treatment with another subsidised LAMA.

Combination Long-Acting Muscarinic Antagonists (LAMA) + Long-Acting Beta2 Agonists (LABA)

TIOTROPIUM + OLODATEROL

Spiolto Respimat®



2.5 mcg/2.5 mcg

Fine mist inhaler

UMECLIDINIUM + VILANTEROL

Anoro Ellipta®



62.5 mcg/25 mcg

Dry powder inhaler

GLYCOPYRRONIUM + INDACATEROL

Ultibro Breezhaler®



50 mcg/110 mcg

Breezhaler®

Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patients who have been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product. Not subsidised if patient is also receiving treatment with a combination ICS and LABA.

Spacers are available free to those who need them on a Practitioners Supply Order (PSO). Contact Manatū Hauora Ministry of Health for an order form on 0800 353 2425. Everyone should have an action plan. Find a range of management plans at asthmafoundation.org.nz

 Funded  Not funded  Partially funded

 Funded by endorsement  Funded by Special Authority

Funding information updated as of 1 September 2022.
Visit www.pharmac.govt.nz

DOWNLOAD AT:
nzrespiratoryguidelines.co.nz